Cabergoline is a potent, long-acting ergoline dopamine D2 receptor agonist. D2 receptor activation on lactotroph cells in the anterior pituitary strongly inhibits prolactin synthesis and release. Prolactin suppression is dose-dependent and sustained — once or twice weekly dosing sufficient due to 63-69 hour half-life. Used in research models of hyperprolactinaemia, prolactin-mediated HPG axis suppression, and dopaminergic reward pathway studies.
Cabergoline is FDA-approved for hyperprolactinaemia and prolactinoma. Reference compound for prolactin suppression research. D2 agonism at lactotrophs reduces PRL secretion >90% at therapeutic doses. Used in pituitary adenoma (prolactinoma) research models — tumour shrinkage data in prolactin-secreting adenomas.
HPG Axis Restoration — Prolactin Suppression
Prolactin inhibits GnRH pulsatility and directly suppresses testosterone synthesis. In high-prolactin states (common with opioid use, antipsychotics, or post-cycle in research models), cabergoline normalises prolactin and restores LH/FSH pulsatility. Used alongside SERM/AI in comprehensive HPG axis research.
Dopaminergic Reward Research
D2/D3 receptor agonism — cabergoline used in dopamine receptor pharmacology, addiction models, and reward circuitry research beyond its prolactin-suppressing effects.
Prolactinoma Shrinkage Research
Cabergoline >bromocriptine in prolactinoma shrinkage: 83% vs 59% normalisation rates. Reference agent for pituitary tumour research, less data with bromocriptine as comparator.
Key Research Data
Study / Source
Key Findings
Webster et al. 1994 NEJM
Cabergoline vs bromocriptine in hyperprolactinaemia: superior PRL normalisation (83% vs 59%), better tolerability
Molitch 2005 NEJM Review
Cabergoline as standard of care for prolactinomas — comprehensive review of tumour shrinkage, PRL normalisation data
TRT + cabergoline models
Cabergoline use in exogenous androgen research to control prolactin elevation — HPG axis companion protocol data
Specifications
Format
Oral tablet — 0.25mg per tablet
Purity
≥99% HPLC
Identity
MS confirmed
Storage
Room temperature, protect from light
Dosing frequency
Long half-life allows twice-weekly dosing in research
Frequently Asked Questions
What is Cabergoline (Dostinex)?
Cabergoline (Dostinex) is a Dopamine D2 receptor agonist / prolactin inhibitor. Cabergoline is a potent, long-acting ergoline dopamine D2 receptor agonist. D2 receptor activation on lactotroph cells in the anterior pituitary strongly inhibits prolactin synthesis and release. Prolactin suppression is dose-dependent and sustained …
How does Cabergoline work in research models?
Cabergoline is FDA-approved for hyperprolactinaemia and prolactinoma. Reference compound for prolactin suppression research. D2 agonism at lactotrophs reduces PRL secretion >90% at therapeutic doses. Used in pituitary adenoma (prolactinoma) research models — tumour shrinkage data…
What makes Cabergoline different from similar compounds?
Prolactin inhibits GnRH pulsatility and directly suppresses testosterone synthesis. In high-prolactin states (common with opioid use, antipsychotics, or post-cycle in research models), cabergoline normalises prolactin and restores LH/FSH pulsatility. Used alongside SERM/AI in com…
Does QSC ship Cabergoline to the USA?
Yes. QSC Cabergoline ships domestically across the USA and internationally to EU, UK, Canada, and Australia. Every batch carries a Janoshik third-party COA confirming ≥99% HPLC purity and MS identity verification.
